BACKGROUND: Tumor cells continuously evolve over time in response to host pressures. However, explanations as to how tumor cells are influenced by the inflammatory tumor microenvironment over time are, to date, poorly defined. We hypothesized that prognostic biomarkers could be obtained by exploring the expression of inflammation-associated genes between early and late stage lung cancer tumor samples. METHODS: Candidate inflammation-associated genes, apolipoprotein C-1 (APOC1), MMP1, KMO)1, CXCL5, CXCL)7, IL-1α, IL-1β, TNF-α and IL-6 were verified by real-time quantitative polymerase chain reaction. Gene expression profiles and immunofluorescence staining of 30 lung cancer tissues were compared. RESULTS: Expressions of APOC1 and IL-6 mRNA on tumor tissues in late stage disease were significantly higher than in early stage lung cancer samples. Immunofluorescence staining of tumor samples showed that the expression of APOC1 gradually increased from early to late stage in lung cancer patients. The expression levels of IL-6 and APOC1 in tumor samples were positively correlated; however, no prognostic value of APOC1 can be identified in serum samples. CONCLUSIONS: We found that the level of tumor APOC1 was highly expressed in late stage lung cancer. Further research is warranted to determine the molecular mechanisms underlying the cross talk of APOC1 and IL-6 in tumor progression. An expanded sample size marker phase II study may lead to the discovery of new lung cancer therapeutics targeting APOC1.
BACKGROUND:Tumor cells continuously evolve over time in response to host pressures. However, explanations as to how tumor cells are influenced by the inflammatory tumor microenvironment over time are, to date, poorly defined. We hypothesized that prognostic biomarkers could be obtained by exploring the expression of inflammation-associated genes between early and late stage lung cancer tumor samples. METHODS: Candidate inflammation-associated genes, apolipoprotein C-1 (APOC1), MMP1, KMO)1, CXCL5, CXCL)7, IL-1α, IL-1β, TNF-α and IL-6 were verified by real-time quantitative polymerase chain reaction. Gene expression profiles and immunofluorescence staining of 30 lung cancer tissues were compared. RESULTS: Expressions of APOC1 and IL-6 mRNA on tumor tissues in late stage disease were significantly higher than in early stage lung cancer samples. Immunofluorescence staining of tumor samples showed that the expression of APOC1 gradually increased from early to late stage in lung cancerpatients. The expression levels of IL-6 and APOC1 in tumor samples were positively correlated; however, no prognostic value of APOC1 can be identified in serum samples. CONCLUSIONS: We found that the level of tumorAPOC1 was highly expressed in late stage lung cancer. Further research is warranted to determine the molecular mechanisms underlying the cross talk of APOC1 and IL-6 in tumor progression. An expanded sample size marker phase II study may lead to the discovery of new lung cancer therapeutics targeting APOC1.
Entities:
Keywords:
APOC1; RT-PCR; gene-expression profiling; inflammation-associated genes; lung cancer
Authors: A Gonçalves; B Esterni; F Bertucci; R Sauvan; C Chabannon; M Cubizolles; V J Bardou; G Houvenaegel; J Jacquemier; S Granjeaud; X-Y Meng; E T Fung; D Birnbaum; D Maraninchi; P Viens; J-P Borg Journal: Oncogene Date: 2006-02-16 Impact factor: 9.867
Authors: Sunil Singhal; Anil Vachani; Danielle Antin-Ozerkis; Larry R Kaiser; Steven M Albelda Journal: Clin Cancer Res Date: 2005-06-01 Impact factor: 12.531
Authors: Dan J Raz; M Roshni Ray; Jae Y Kim; Biao He; Miquel Taron; Marcin Skrzypski; Mark Segal; David R Gandara; Rafael Rosell; David M Jablons Journal: Clin Cancer Res Date: 2008-09-01 Impact factor: 12.531
Authors: Nancy L Guo; Ying-Wooi Wan; Kursad Tosun; Hong Lin; Zola Msiska; Daniel C Flynn; Scot C Remick; Val Vallyathan; Afshin Dowlati; Xianglin Shi; Vincent Castranova; David G Beer; Yong Qian Journal: Clin Cancer Res Date: 2008-12-15 Impact factor: 12.531
Authors: Zoe Hall; Catherine H Wilson; Deborah L Burkhart; Tom Ashmore; Gerard I Evan; Julian L Griffin Journal: J Lipid Res Date: 2020-08-04 Impact factor: 5.922